Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes

Journal of Pathology

Volumn 216, Issue 4, 2008, Pages 451-459

  Lacreusette, A ^a,b   Lartigue, A ^a,b,f   Nguyen, J M ^c   Barbieux, I ^a,b   Pandolfino, M C ^a,b,d   Paris, F ^a,b   Khammari, A ^a,b,d   Dreno B ^a,b,d   Jacques, Y ^a,b   Blanchard, F ^b,e   Godard, A ^a,b,d  

^a Team 12   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c PIMESP   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e INSERM   (France)

^f CNRS Aix Marseille University   (France)

Author keywords

Interleukin 6; Lymph nodes; Melanoma xenograft tumours in nude mice; Oncostatin M; Retrospective study of relapse free survival; Stage III human melanoma; Tumour infiltrating lymphocytes

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA; ONCOSTATIN M; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; IMMUNOTHERAPY; MELANOMA; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; XENOGRAFT;

EID: 57149120971     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2416     Document Type: Article

References (49)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
2. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006;20:2149-2182.
3. Wolchok JD, Saenger YM. Current topics in melanoma. Curr Opin Oncol 2007;19:116-120.
4. Flaherty KT. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res 2006;12:s 2366-2370.
5. Wrzesinski C, Restifo NP. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol 2005;17:195-201.
6. Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002;51:539-546.
7. Khammari A, Nguyen JM, Pandolfino MC, Quereux G, Brocard A, Bercegeay S, et al. Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2007;56:1853-1860.
8. Labarriere N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, Dreno B, et al. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 2002;51:532-538.
9. Benlalam H, Vignard V, Khammari A, Bonnin A, Godet Y, Pandolfino MC, et al. Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol Immunother 2007;56:515-526.
10. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-3968.
11. Quereux G, Pandolfino MC, Knol AC, Khammari A, Volteau C, Nguyen JM, et al. Tissue prognostic markers for adoptive immunotherapy in melanoma. Eur J Dermatol 2007;17:295-301.
12. Hofbauer GF, Burkhart A, Schuler G, Dummer R, Burg G, Nestle FO. High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma. J Immunother (1997) 2004;27:73-78.
13. van Houdt IS, Oudejans JJ, van den Eertwegh AJ, Baars A, Vos W, Bladergroen BA, et al. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res 2005;11:6400-6407.
14. Takeuchi H, Morton DL, Elashoff D, Hoon DS. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer 2005;117:1032-1038.
15. Mori T, O'Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 2005;23:9351- 9358.
16. van Horssen R, Rens JA, Brunstein F, Guns V, van Gils M, Hagen TL, et al. Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion. Int J Cancer 2006;119:1481-1490.
17. Boudny V, Dusek L, Adamkova L, Chumchalova J, Kocak I, Fait V, et al. Lack of STAT 1 phosphorylation at TYR 701 by IFNgamma correlates with disease outcome in melanoma patients. Neoplasma 2005;52:330-337.
18. Lesinski GB, Valentino D, Hade EM, Jones S, Magro C, Chaudhury AR, et al. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother 2005;54:815-825.
19. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994;69:911-913.
20. Tas F, Oguz H, Argon A, Duranyildiz D, Camlica H, Yasasever V, et al. The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med Oncol 2005;22:241-246.
21. Mouawad R, Khayat D, Merle S, Antoine EC, Gil-Delgado M, Soubrane C. Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy? Melanoma Res 1999;9:181-188.
22. Bani MR, Rak J, Adachi D, Wiltshire R, Trent JM, Kerbel RS, et al. Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype. Cancer Res 1996;56:3075-3086.
23. Lu C, Rak JW, Kobayashi H, Kerbel RS. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions. Cancer Res 1993;53:2708-2711.
24. Yu D, Thomas-Tikhonenko A. Intratumoral delivery of an interferon gamma retrovirus-producing cells inhibits growth of a murine melanoma by a non-immune mechanism. Cancer Lett 2001;173:145-154.
25. Ozbek S, Peters M, Breuhahn K, Mann A, Blessing M, Fischer M, et al. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. Oncogene 2001;20:972-979.
26. Ouyang L, Shen LY, Li T, Liu J. Inhibition effect of Oncostatin M on metastatic human lung cancer cells 95-D in vitro and on murine melanoma cells B16BL6 in vivo. Biomed Res 2006;27:197-202.
27. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 2003;149:39-52.
28. Boniface K, Diveu C, Morel F, Pedretti N, Froger J, Ravon E, et al. Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol 2007;178:4615-4622.
29. Sugaya M, Fang L, Cardones AR, Kakinuma T, Jaber SH, Blauvelt A, et al. Oncostatin M enhances CCL21 expression by microvascular endothelial cells and increases the efficiency of dendritic cell trafficking to lymph nodes. J Immunol 2006;177:7665-7672.
30. Grant SL, Begley CG. The oncostatin M signalling pathway: reversing the neoplastic phenotype? Mol Med Today 1999;5:406-412.
31. Lacreusette A, Nguyen JM, Pandolfino MC, Khammari A, Dreno B, Jacques Y, et al. Loss of oncostatin M receptor beta in metastatic melanoma cells. Oncogene 2007;26:881-892.
32. Pandolfino MC, Labarriere N, Tessier MH, Cassidanius A, Bercegeay S, Lemarre P, et al. High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement. Cancer Immunol Immunother 2001;50:134-140.
33. Wallace PM, Macmaster JF, Rillema JR, Rouleau KA, Hanson MB, Burstein SA, et al. In vivo properties of oncostatin M. Ann N Y Acad Sci 1995;762:42-54.
34. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004;173:7125-7130.
35. Shen X, Zhou J, Hathcock KS, Robbins P, Powell DJ Jr, Rosenberg SA, et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother (1997) 2007;30:123-129.
36. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, et al. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves up-regulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene 1999;18:3742-3753.
37. Florenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, et al. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene 1999;18:1023-1032.
38. Musso T, Badolato R, Longo DL, Gusella GL, Varesio L. Leukaemia inhibitory factor induces interleukin-8 and monocyte chemotactic and activating factor in human monocytes: differential regulation by interferon-γ. Blood 1995;86:1961-1967.
39. Zheng X, Knight DA, Zhou D, Weir T, Peacock C, Schellenberg RR, et al. Leukaemia inhibitory factor is synthesized and released by human eosinophils and modulates activation state and chemotaxis. J Allergy Clin Immunol 1999;104:136-144.
40. Linker RA, Kruse N, Israel S, Wei T, Seubert S, Hombach A, et al. Leukaemia inhibitory factor deficiency modulates the immune response and limits autoimmune demyelination: a new role for neurotrophic cytokines in neuroinflammation. J Immunol 2008;180:2204-2213.
41. Schofield G, Kimber SJ. Leukocyte subpopulations in the uteri of leukaemia-inhibitory factor knockout mice during early pregnancy. Biol Reprod 2005;72:872-878.
42. Villiger PM, Geng Y, Lotz M. Induction of cytokine expression by leukaemia inhibitory factor. J Clin Invest 1993;91:1575-1581.
43. Zhu M, Oishi K, Lee SC, Patterson PH. Studies using leukaemia inhibitory factor (LIF) knockout mice and a LIF adenoviral vector demonstrate a key anti-inflammatory role for this cytokine in cutaneous inflammation. J Immunol 2001;166:2049-2054.
44. Escary JL, Perreau J, Dumenil D, Ezine S, Brulet P. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature 1993;363:361-364.
45. Brounais B, Chipoy C, Mori K, Charrier C, Battaglia S, Pilet P, et al. Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the anti-tumor effect of midostaurin in vivo. Clin Cancer Res 2008;14:5400-5409.
46. Loy JK, Davidson TJ, Berry KK, Macmaster JF, Danle B, Durham SK. Oncostatin M: development of a pleiotropic cytokine. Toxicol Pathol 1999;27:151-155.
47. Olencki T, Finke J, Tubbs R, Elson P, McLain D, Herzog P, et al. Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effects. J Immunother 2000;23:549-556.
48. Blanchard F, Kinzie E, Wang Y, Duplomb L, Godard A, Held WA, et al. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins. Oncogene 2002;21:6264-6277.
49. Staunton D, Hudson KR, Heath JK. The interactions of the cytokine-binding homology region and immunoglobulin-like domains of gp130 with oncostatin M: implications for receptor complex formation. Protein Eng 1998;11:1093-1102.